CoRegen Announces The Appointment Of Dr. Sonal Gupta As Chief Medical Officer To Strengthen Biotech Leadership

CoRegen, a biopharmaceutical company focused on developing innovative treatments for some of the most aggressive cancers, has appointed Dr. Sonal Gupta as its new Chief Medical Officer. In this role, Dr. Gupta will lead the clinical strategy supporting CoRegen’s mission to target and alter the steroid receptor coactivator-3 (SRC-3) gene, a critical driver in many solid tumors, to improve outcomes for patients with limited treatment options.

Dr. Gupta brings close to two decades of experience in clinical development across the biotech and pharmaceutical sectors. Her background includes extensive work in oncology, rare diseases, cell and gene therapy, and translational medicine. Prior to joining CoRegen, she served as Senior Vice President and Head of Clinical Development at AffyImmune Therapeutics, where she led the restart and expansion of clinical trials involving autologous CAR T-cell therapies, particularly in non-small cell lung cancer and rare tumor types.

Before AffyImmune, Dr. Gupta was Head of Translational Medicine at AVROBIO, where she oversaw gene therapy programs targeting Gaucher, Fabry, and Pompe diseases. She has also held senior clinical roles at Rubius Therapeutics, CRISPR Therapeutics, and Selecta Biosciences, contributing to programs focused on sickle cell disease, thalassemia, and solid tumors.

Suneet Varma, Chairman of the Board at CoRegen, stated, “Dr. Gupta joins CoRegen as we prepare to advance our SRC-3 platform into the clinic. As a physician-scientist, she brings a unique combination of clinical development expertise, translational science leadership, and deep regulatory experience across oncology and rare disease. Her proven track record of leading innovative programs through critical milestones, from trial design and execution to FDA and global regulatory engagement, makes her an invaluable addition to our team. As we accelerate our transition to a clinical-stage company, her strategic insight and executional strength will be instrumental in advancing our platform and delivering meaningful impact for patients.”

Dr. Gupta mentioned, "CoRegen’s innovative approach to solid tumors and its commitment to improving patient outcomes align with my own passion for advancing medicine through collaboration and scientific excellence. I look forward to working closely with the team to drive our clinical and regulatory strategies forward."

Her expertise spans investigational new drug (IND) strategy, biomarker development, and collaboration with global regulatory bodies. Dr. Gupta holds an M.D. from Government Medical College in Surat, India, and a Ph.D. in cancer biology and immunology from the University of Bradford in the United Kingdom. She has authored several peer-reviewed publications and has served as a scientific and clinical advisor across both industry and academic settings.